Paul Hastings Advises Stifel in X4 Pharmaceuticals’ PIPE Financing

Paul Hastings LLP advised Stifel as sole placement agent in connection with X4 Pharmaceuticals’ (Nasdaq: XFOR) $60 million private placement in public equity financing. The financing is expected to close on or about August 13, 2025, subject to customary closing conditions.

Equity Capital Markets and Corporate Life Sciences chair Seo Salimi and of counsel Ryan Brewer led the Paul Hastings team.

More details can be found here.

About Paul Hastings
With widely recognized elite teams across 17 core practices, Paul Hastings is a premier law firm with a culture of excellence focused on providing intellectual capital and superior execution globally to the world’s leading investment banks, asset managers and corporations.